Parke A L
University of Connecticut Health Center, Department of Medicine, Farmington, CT 06030-1310.
Lupus. 1993 Feb;2 Suppl 1:S21-3.
Disease activity has been demonstrated to be one of the major factors contributing to fetal loss in SLE patients, and discontinuation of antimalarial therapy can precipitate a flare of disease. It is therefore important to determine whether it is safe to continue antimalarial therapy throughout pregnancy. We have previously stated that we consider lupus patients and their fetuses to be at risk for disaster if antimalarial therapy is discontinued during pregnancy, and it has been our experience that lupus patients can produce normal offspring even if they are taking daily chloroquine or hydroxychloroquine. Several other reports now support our findings that it is probably safe to continue antimalarial therapy during pregnancy, although there are no large studies published. Data on the secretion of hydroxychloroquine in the breast milk of patients on steady-state hydroxychloroquine therapy are minimal, and further studies are required to determine whether these women can safely nurse their infants while taking hydroxychloroquine daily.
疾病活动已被证明是导致系统性红斑狼疮（SLE）患者胎儿丢失的主要因素之一，停用抗疟治疗可促使疾病复发。因此，确定整个孕期持续进行抗疟治疗是否安全很重要。我们之前曾表示，如果孕期停用抗疟治疗，我们认为狼疮患者及其胎儿将面临灾难风险，并且我们的经验是，即使狼疮患者每日服用氯喹或羟氯喹，她们也能生出正常后代。现在其他几份报告支持了我们的研究结果，即孕期持续进行抗疟治疗可能是安全的，尽管尚无大型研究发表。关于接受稳态羟氯喹治疗的患者母乳中羟氯喹分泌的数据极少，需要进一步研究以确定这些女性在每日服用羟氯喹时能否安全地哺乳婴儿。
